An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms

Completed · Phase 3 · Has a placebo group

Conditions studied: Erectile Dysfunction, Lower Urinary Tract Symptoms

In brief

The purpose of this study is to assess the effect of Alfuzosin in treating Erectile Dysfunction in men with mild lower urinary tract symptoms based upon a change from baseline in erectile function (EF) domain of International Index of Erectile Function (IIEF).

Key facts

Study ID

NCT00893113

Run by

Chesapeake Urology Research Associates

People needed

74

Starts

2009-06-01

Expected to finish

2012-10-01

Last updated by the study team

2018-03-09

Who can join

Age: 30 and older, up to 69. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Male, 30-69 years of age
• Has mild to moderate Erectile Dysfunction with a score < 25 on EF domain in IIEF
• AUA score of less than or equal to 14
• Negative urinalysis with no evidence of a Urinary Tract Infection

You may not qualify if…

• Blood pressure < 90/50 or > 170/110
• Neurological disorder (MS, SCI, CVA, Parkinson's disease, ALS)
• Diabetes Mellitus
• History of PSA > 10
• History of confirmed or suspected prostate cancer
• History of Moderate/Severe Hepatic Insufficiency defined as > 2X ULN
• On Alpha Blocker or PDE 5 inhibitor within 2 weeks of randomization
• Receive treatment with other investigational agents within 30 days prior to enrollment

Where it is running

• Chesapeake Urology Research Associates — Baltimore, Maryland, United States
• Chesapeake Urology Research Associates — Baltimore, Maryland, United States
• Chesapeake Urology Research Associates — Glen Burnie, Maryland, United States
• Chesapeake Urology Research Associates — Towson, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.